CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-27 | Azelby Robert President & CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2022-01-27 | Morisset Valerie EVP, R&D and CSO | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2022-01-27 | Bucher James B EVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2021-08-12 | AI ETI LLC 10% owner | Conversion | +4,209,400 | 4,209,400 | ||
| 2021-08-12 | AI ETI LLC 10% owner | Purchase | +800,000 | $12.50 | $10.0M | 5,009,400 |
| 2021-08-12 | AI ETI LLC 10% owner | Conversion · Series A Redeemable Convertible Preferred Stock | −3,568,375 | 0 | ||
| 2021-08-12 | AI ETI LLC 10% owner | Conversion · Series B Redeemable Convertible Preferred Stock | −641,025 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +4,727,585 | 7,594,804 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +3,004,782 | $12.50 | $37.6M | 10,599,586 |
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,226,497 | 1,226,497 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +288,461 | 288,461 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +195,218 | $12.50 | $2.4M | 483,679 |
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +624,974 | 841,087 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −2,639,507 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-1 Preferred Stock | −1,415,002 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −673,076 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −708,333 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-1 Preferred Stock | −518,164 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −288,461 | 0 | ||
| 2021-08-12 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A Preferred Stock | −485,493 | 0 |
Page 8 of 9 · 166 trades